Pegylated interferon alfa-2a (PEG)

Phase 3Small molecule

Pegylated interferon alfa-2a (PEG) is one of 62 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Pegylated interferon alfa-2a (PEG)

Roche

Phase 3

5 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis5 trials

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Completed· Roche logo

Roche·Phase 3·NCT01095835·131 enrolled

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Completed· Roche logo

Roche·Phase 2·NCT01706575·76 enrolled

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Completed· Roche logo

Roche·Phase 3·NCT02732639·31 enrolled

Show 2 more trials

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Completed· Roche logo

Roche··NCT02850289·385 enrolled

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Terminated· Roche logo

Roche··NCT02118597·19 enrolled

Hepatitis C3 trials

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01616524·880 enrolled

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

Completed· Roche logo

Roche·Phase 2·NCT02716779·68 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00947349·22 enrolled

Treatment1 trial

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00991289·68 enrolled

Age1 trial

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01309932·165 enrolled

HCV Infection1 trial

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01846832·232 enrolled

1 more indication

Trial1 trial

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01054573·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Pegylated interferon alfa-2a (PEG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated interferon alfa-2a (PEG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated interferon alfa-2a (PEG). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Pegylated interferon alfa-2a (PEG)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis5 trials

Hepatitis C3 trials

Treatment1 trial

Age1 trial

HCV Infection1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News